www.mayoclinic.org
Dec 20, 2024, 06:53
Nathan Punwani: The cost-effectiveness of TKI’s used in chronic myeloid leukemia
Nathan Punwani, Blood and Marrow Transplant Physician at Mayo Clinic, shared a post on LinkedIn, about paper by him as first author, published in The New England Journal of Medicine.
“I’m in the New England Journal of Medicine!
I discuss the cost-effectiveness of different tyrosine kinase inhibitor (TKI) drugs used in the management of chronic myeloid leukemia (CML) like the newly approved asciminib.
This is probably the first time anyone has cited Mark Cuban and Mark Cuban Cost Plus Drug Company, PBC as a reference in the NEJM Group!”
“Asciminib in Newly Diagnosed Chronic Myeloid Leukemia”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 20, 2024, 06:17
Dec 20, 2024, 02:17
Dec 20, 2024, 02:15
Dec 20, 2024, 02:13
Dec 20, 2024, 02:10
Dec 20, 2024, 02:09
Dec 20, 2024, 01:27